Bloodstream infections caused by Enterobacter species: Predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome

Clinical Infectious Diseases

Volumn 39, Issue 6, 2004, Pages 812-818

  Kang, Cheol In ^a   Kim, Sung Han ^a   Wan, Beom Park ^a   Lee, Ki Deok ^a   Kim, Hong Bin ^a   Oh, Myoung Don ^a,b   Kim, Eui Chong ^a,b   Choe, Kang Won ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; ENTEROBACTER AEROGENES; ENTEROBACTER AMNIGENUS; ENTEROBACTER ASBURIAE; ENTEROBACTER CLOACAE; ENTEROBACTER GERGOVIAE; ENTEROBACTER HORMAECHEI; ENTEROBACTER INFECTION; ENTEROBACTER SAKAZAKII; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PANTOEA AGGLOMERANS; PREDICTION; PRIMARY INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APACHE; BACTEREMIA; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN RESISTANCE; CROSS INFECTION; ENTEROBACTER; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 4544263543     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/423382     Document Type: Article

References (21)

1. Sanders WE, Sanders CC. Enterobacter spp: a pathogen poised to flourish at the turn of the century. Clin Microbiol Rev 1997; 10:220-42.
2. Blot SI, Vandewoude KH, Colardyn FA. Evaluation of outcome in critically ill patients with nosocomial Enterobacter bacteremia: results of a matched cohort study. Chest 2003; 123:1208-13.
3. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27:520-32.
4. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
5. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162:185-90.
6. Schwaber MJ, Graham CS, Sands BE, Gold HS, Carmeli Y. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother 2003; 47:1882-6.
7. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002; 34:1600-6.
8. Jorgensen JH, Turnidge JD, Washington JA. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 7th ed. Washington, DC: ASM Press, 1999:1526-43.
9. NCCLS. Performance standards for antimicrobial disk susceptibility tests. NCCLS document M100-S12. Wayne, PA: NCCLS, 2000.
10. Knaus WA, Drapier EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
11. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
12. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-40.
13. Dahmash NS, Chowdhury NH, Fayed DF. Septic shock in critically ill patients: etiology, management and outcome. J Infect 1993; 26:159-70.
14. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001; 45:2628-30.
15. Johnson MP, Ramphal R. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990; 162:981-3.
16. Lee SO, Kim YS, Kim BN, Kim MN, Woo JH, Ryu J. Impact of previous use of antibiotics on development of resistance to extended-spectrum cephalosporins in patients with Enterobacter bacteremia. Eur J Clin Microbiol Infect Dis 2002; 21:577-81.
17. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-51.
18. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med 1996; 156:2121-6.
19. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-35.
20. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127-33.
21. Siebert JD, Thomson RB Jr, Tan JS, Gerson LW. Emergence of antimicrobial resistance in gram-negative bacilli causing bacteremia during therapy. Am J Clin Pathol 1993; 100:47-51.